{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T02:40:02Z","timestamp":1773369602236,"version":"3.50.1"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100009878","name":"Regione Veneto","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009878","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejinme.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Internal Medicine"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.ejim.2021.12.023","type":"journal-article","created":{"date-parts":[[2021,12,26]],"date-time":"2021-12-26T22:32:53Z","timestamp":1640557973000},"page":"42-49","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Outcome of SARS CoV-2 inpatients treated with convalescent plasma: One-year of data from the Veneto region (Italy) Registry"],"prefix":"10.1016","volume":"97","author":[{"given":"Giustina","family":"De Silvestro","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Piero","family":"Marson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimo","family":"La Raja","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna Maria","family":"Cattelan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriella","family":"Guarnieri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacopo","family":"Monticelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivo","family":"Tiberio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Vianello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giorgio","family":"Gandini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gianluca","family":"Gessoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Fiorin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Corrado","family":"Sardella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Astolfi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario","family":"Saia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejim.2021.12.023_bib0001","article-title":"Convalescent plasma therapy for COVID-19: a graphical mosaic of the worldwide evidence","volume":"8","author":"Klassen","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.ejim.2021.12.023_bib0002","doi-asserted-by":"crossref","DOI":"10.1016\/j.transci.2021.103154","article-title":"Preparedness and activities of the anti-SARS-CoV-2 convalescent plasma bank in the Veneto region (Italy): an organizational model for future emergencies","author":"De Silvestro","year":"2021","journal-title":"Transfus Apher Sci"},{"key":"10.1016\/j.ejim.2021.12.023_bib0003","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0166-3542(00)00111-X","article-title":"Antibodies for the prevention and treatment of viral diseases","volume":"47","author":"Sawyer","year":"2000","journal-title":"Antiviral Res"},{"key":"10.1016\/j.ejim.2021.12.023_bib0004","first-page":"152","article-title":"Convalescent plasma: new evidence for an old therapeutic tool?","volume":"14","author":"Marano","year":"2016","journal-title":"Blood Transfus"},{"key":"10.1016\/j.ejim.2021.12.023_bib0005","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.tracli.2015.12.003","article-title":"Plasma therapy against pathogens, as of yesterday, today and tomorrow","volume":"23","author":"Garraud","year":"2016","journal-title":"Transfus Clin Biol"},{"key":"10.1016\/j.ejim.2021.12.023_bib0006","article-title":"Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review","volume":"5","author":"Piechotta","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ejim.2021.12.023_bib0007","doi-asserted-by":"crossref","first-page":"4791","DOI":"10.1172\/JCI140200","article-title":"Early safety indicators of COVID-19 convalescent plasma in 5,000 patients","volume":"130","author":"Joyner","year":"2020","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ejim.2021.12.023_bib0008","series-title":"Blood product safety. statpearls [Internet], treasure islands (FL)","author":"Harris","year":"2020"},{"key":"10.1016\/j.ejim.2021.12.023_bib0009","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/S1473-3099(20)30141-9","article-title":"Convalescent plasma as a potential therapy for COVID-19","volume":"20","author":"Chen","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ejim.2021.12.023_bib0010","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1016\/S0140-6736(21)00469-4","article-title":"Guidelines should not pool evidence from uncomplicated and severe COVID-19","volume":"397","author":"White","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.ejim.2021.12.023_bib0011","doi-asserted-by":"crossref","first-page":"m3939","DOI":"10.1136\/bmj.m3939","article-title":"Convalescent plasma in the management of moderate COVID-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial)","volume":"371","author":"Agarwal","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.ejim.2021.12.023_bib0012","doi-asserted-by":"crossref","unstructured":"Salazar M.R., Gonzalez S.E., Regairaz L., Ferrando N.S., Gonzalez Martinez V.V., Carrera Ramos P.M., et\u00a0al. Effect of convalescent plasma on mortality in patients with COVID-19 pneumonia. medRxiv preprint. October 2020. https:\/\/doi.org\/10.1101\/2020.10.08.20202606.","DOI":"10.1101\/2020.10.08.20202606"},{"key":"10.1016\/j.ejim.2021.12.023_bib0013","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1056\/NEJMoa2031304","article-title":"A randomized trial of convalescent plasma in Covid-19 severe pneumonia","volume":"384","author":"Simonovich","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2021.12.023_bib0014","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.ajpath.2020.10.008","article-title":"Significantly decreased mortality in a large cohort of Coronavirus disease 2019 (COVID-19) patients transfused early with convalescent plasma containing high-titer anti-severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) spike protein Ig","volume":"191","author":"Salazar","year":"2021","journal-title":"Am J Pathol"},{"key":"10.1016\/j.ejim.2021.12.023_bib0015","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1056\/NEJMoa2031893","article-title":"Convalescent plasma antibody levels and the risk of death from Covid-19","volume":"384","author":"Joyner","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2021.12.023_bib0016","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1016\/S0140-6736(21)00897-7","article-title":"Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial","volume":"397","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.ejim.2021.12.023_bib0017","doi-asserted-by":"crossref","first-page":"e69866","DOI":"10.7554\/eLife.69866","article-title":"Convalescent plasma use in the USA was inversely correlated with COVID-19 mortality","volume":"10","author":"Casadevall","year":"2021","journal-title":"Elife"},{"key":"10.1016\/j.ejim.2021.12.023_bib0018","doi-asserted-by":"crossref","DOI":"10.1172\/JCI152264","article-title":"Results of the CAPSID randomized trial for high-dose convalescent plasma in patients with severe COVID-19","volume":"131","author":"K\u00f6rper","year":"2021","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ejim.2021.12.023_bib0019","unstructured":"https:\/\/www.aifa.gov.it\/-\/covid-19-studio-tsunami-il-plasma-non-riduce-il-rischio-di-peggioramento-respiratorio-o-morte."},{"key":"10.1016\/j.ejim.2021.12.023_bib0020","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1001\/jama.2020.10044","article-title":"Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: a randomized clinical trial","volume":"324","author":"Li","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.ejim.2021.12.023_bib0021","unstructured":"National Health Council. Document detailing the criteria for SARS-CoV-2 testing via nasopharyngeal swab and diagnostic test in clinically asymptomatic subjects, 28 February 2020."},{"key":"10.1016\/j.ejim.2021.12.023_bib0022","unstructured":"Veneto Region, Azienda Zero. Progress report of the COVID-19 epidemic in Veneto Data updated to 06\/17\/2021."},{"key":"10.1016\/j.ejim.2021.12.023_bib0023","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0254258","article-title":"Variable effects of underlying diseases on the prognosis of patients with COVID-19","volume":"16","author":"Choi","year":"2021","journal-title":"PloS One"},{"key":"10.1016\/j.ejim.2021.12.023_bib0024","doi-asserted-by":"crossref","first-page":"33","DOI":"10.7326\/M20-3905","article-title":"Patient trajectories among persons hospitalized for COVID-19: a cohort study","volume":"174","author":"Garibaldi","year":"2021","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ejim.2021.12.023_bib0025","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1007\/s40520-021-01914-y","article-title":"Comorbidity status of deceased COVID-19 in-patients in Italy","volume":"33","author":"Vetrano","year":"2021","journal-title":"Aging Clin Exp Res"},{"key":"10.1016\/j.ejim.2021.12.023_bib0026","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.21037\/apm-20-1863","article-title":"Clinical characteristics, laboratory abnormalities and CT findings of COVID-19 patients and risk factors of severe disease: a systematic review and meta-analysis","volume":"10","author":"Xie","year":"2021","journal-title":"Ann Palliat Med"},{"key":"10.1016\/j.ejim.2021.12.023_bib0027","article-title":"Effect of time and titer in convalescent plasma therapy fdor COVID-19","volume":"20","author":"De Candia","year":"2021","journal-title":"iScience"},{"key":"10.1016\/j.ejim.2021.12.023_bib0028","doi-asserted-by":"crossref","first-page":"599","DOI":"10.7326\/0003-4819-145-8-200610170-00139","article-title":"Meta-analysis: convalescent blood products for Spanish Influenza pandemic: a future H5N1 treatment?","volume":"145","author":"Luke","year":"2006","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ejim.2021.12.023_bib0029","doi-asserted-by":"crossref","DOI":"10.1016\/j.transci.2021.103063","article-title":"A look-back at convalescent plasma to trat COVID-19","volume":"60","author":"Garraud","year":"2021","journal-title":"Transf Apher Sci"},{"key":"10.1016\/j.ejim.2021.12.023_bib0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.healun.2021.04.017","article-title":"Immune response to COVID-19 in older adults","author":"Jergovic","year":"2021","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.ejim.2021.12.023_bib0031","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2020.101205","article-title":"Aging in COVID-19: vulnerability, immunity and intervention","volume":"65","author":"Chen","year":"2021","journal-title":"Aging Res Rev"},{"key":"10.1016\/j.ejim.2021.12.023_bib0032","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1016\/j.mayocp.2021.02.008","article-title":"The effect of convalescent plasma therapy on COVID-19 patient mortality: systematic review and meta-analysis","volume":"96","author":"Klassen","year":"2021","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.ejim.2021.12.023_bib0033","first-page":"4841","article-title":"Plasma convalescent decrease mortality in COVID-19 patients: a systematic review and meta-analysis","volume":"25","author":"Yuwono Soeroto","year":"2021","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"10.1016\/j.ejim.2021.12.023_bib0034","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1016\/j.mayocp.2020.06.028","article-title":"Safety update: COVID-19 convalescent plasma in 20,000 hospitalized patients","volume":"95","author":"Joyner","year":"2020","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.ejim.2021.12.023_bib0035","article-title":"Assessment of the safety and therapeutic benefits of convalescent plasma in COVID-19 treatment: a systematic review and meta-analysis","volume":"6","author":"Ferreira Barreira","year":"2021","journal-title":"Front Med (Lausanne)"}],"container-title":["European Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620521004337?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620521004337?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T09:35:36Z","timestamp":1760607336000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0953620521004337"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":35,"alternative-id":["S0953620521004337"],"URL":"https:\/\/doi.org\/10.1016\/j.ejim.2021.12.023","relation":{},"ISSN":["0953-6205"],"issn-type":[{"value":"0953-6205","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Outcome of SARS CoV-2 inpatients treated with convalescent plasma: One-year of data from the Veneto region (Italy) Registry","name":"articletitle","label":"Article Title"},{"value":"European Journal of Internal Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejim.2021.12.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}